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Background: Most Cardiomyopathies are inherited diseases with auto-
somal dominant inheritance and delayed cardiac expression. In families with
a documented causal mutation, predictive genetic testing can be proposed to
“healthy” relatives to appropriately manage medical follow-up. Psychological
impact of predictive genetic testing is however poorly described in these
diseases.
Aim and methods: We performed a prospective study about the psycho-
logical impact of predictive genetic testing in adults seen in our out-patient
multidisciplinary consultation (cardiologist, genetic counsellor, and psycho-
logist). Self-report questionnaires were proposed during the initial consultation
(Q1) and 1 to 3 month after genetic result was given (Q2). Questionnaires
used validated scales to evaluate anxiety, depression, hopelessness, self-
esteem, impact of announcement, quality of life (QOL), and motivations.
Results: Sixty-six adults completed questionnaire Q1 and 38 completed
questionnaire Q2 (15 mutation carriers, 23 non carriers). Analysis of psycho-
metric tests revealed no significant modification before/after genetic results.
However, genetic status influenced the level of general anxiety, depression
score and QOL. The consultation process was evaluated as useful (97%) and
reassuring (80%). The interview with the pyschologist was useful especially
for the anticipation of the result (73%). Waiting period (minimal period fixed
between consultation and blood sampling) was evaluated as reassuring (38%)
but unnecessary (91%).
Conclusion: We report on the first French evaluation of the psychological
impact of predictive genetic testing in cardiomyopathies. No deleterious effect
of genetic results was observed. However the study underlines the usefulness
of multidisciplinary management, especially to help the relatives to better
anticipate the genetic result and consequences.
073
Very long-term effects of pacing therapy in Hypertrophic Obstructive
Cardiomyopathy (HOCM)
Adrien Luçon (1), Laurent Palud (2), Erwan Donal (1), Nathalie Behar (1),
Raphael Martins (1), Dominique Pavin (1), Christophe Leclercq (1), Phi-
lippe Mabo (1), Jean-Claude Daubert (1)
(1) Hôpital Pontchaillou CHU de Rennes, Cardiologie, Rennes, France –
(2) Hôpital de Lorient, Cardiologie, Lorient, France
The clinical value of DDD pacing as primary treatment of HOCM remains
controversial. Very long-term data are lacking.
Aims: single-centre observational study aimed at describing the very long
term effects on symptoms, clinical and echocardiographic outcomes
Patients: 54 patients (59±14 years) with symptomatic (NYHA Class >2)
drug-refractory HOCM implanted with a DDD pacemaker with or without
defibrillator between 1991 and 2007 and followed up to 20 years (mean 11.5;
range 0,4-21,8).
Main results are summarised in table. No patient had myomectomy or
septal ablation during follow-up (f/u). NYHA functional class and other symp-
toms were significantly improved at 1-2 years and at the end of f/u. Left ven-
tricular outflow tract (LVOT) gradient decreased by a mean of 78% at 1-2
years and 89% at end f/u consistent with SAM resolution. LV ejection fraction
decreased over time with a mean value of 56% at end f/u without evidence of
cavity dilatation. The actuarial survival rate was 90% at 5-yrs and 65% at
10-yrs. 24 patients died, 19 from non cardiac cause and 5 cardiovascular.
2 patients had heart transplant after 8 and 13 yrs.
Conclusion: The clinical and echocardiographic outcome of HOCM
patients treated by DDD pacing seems favourable, inviting to re-evaluate the
exact value of the therapy in further controlled studies
Table – Main results
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Background: Transthyretin (TTR) familial amyloid polyneuropathy (FAP)
is a fatal autosomal dominant neurodegenerative disease characterized by
deposition of transthyretin targeting mainly the peripheral nervous system and
the heart. Early noninvasive detection of cardiac impairment is of importance
for the therapeutic management.
Aim: Assess if natriuretic peptide (NT-proBNP) or troponin T (cTnT) are
reliable biomarkers to predict echocardiographic left ventricle (LV) impair-
ment in a wide variety of TTR patients.
Methods: 36 asymptomatic carriers and patients with proven FAP genetic
mutation had clinical, biological and echocardiography assessment of left ven-
tricle (LV) systolic function (SD), filling pressure (FP) and hypertrophy
(LVH) as marker of amyloid deposition
Results: In the all cohort, the median (IQR) age, NT-proBNP, LV ejection
fraction were respectively 59 (41-74), 323pg/ml (58-1960) and 60% (51-66).
64% were men and 12 had an increased in cTnT. TTR gene mutations preva-
lence was 50% for Val30Met. 4 patients were asymptomatic, 6 had only neu-
rologic clinical signs and 26 had echo-LV abnormalities with or without
neurologic disorders. Their median NT-proBNP value were respectively: 33
(19-50), 54 (37-154) and 747 (253;2840). Using received-operator curve,
NTproBNP identified significantly patients with echo-LV abnormalities
(Area : 0.92;(0.83-0.99), p=0.001) with a threshold above 82pg/ml and a sen-
sitivity of 92% and specificity of 90%. Elevated cTnT (superior to 0.01ng/ml)
was only observed in patients combining impairment of LVH and SD or LVH,
SD and FP.
Baseline 3 months 1-2 years End f/u P value
NYHA functional 
class, (%)
< 0,0001
Grade 1 0 31 35 36
Grade 2 43 53 59 57
Grade 3 52 16 6 7
Grade 4 5 0 0 0
Syncope/near-
syncope (%)
76/48 2/2 2/2 2/2 <0,0001
Angina (%) 57 4 4 4 <0,0001
LVOT gradient 
(mmHg)
79±36 20±24 11±15 8±21 <0,0001
SAM (%) 96 38 30 16 <0,0001
LVEF (%) 63,5±7,5 61±7 59±7 56±9 0,05
LVEDD (%) 47±5 NA NA 43±12 0,34
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Conclusion: In TTR amyloidosis, NTproBNP and troponin T are associ-
ated with LV impairment measured by echocardiography suggesting that
NTproBNP could be useful in FAP carriers to start echocardiographic follow-
up whereas troponin would identify patients with severe cardiac disease.
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Background: Transthyretin familial amyloid polyneuropathy (TTR-FAP)
is an autosomal dominant disease characterized by extracellular amyloid
deposition in the nerves and heart. Orthotopic liver transplant (OLT) is recom-
mended to remove the source of mutated TTR and stop amyloid deposition.
However, progressive cardiomyopathy due to continuing amyloidosis has been
described following OLT in patients with non-V30M mutations. Tafamidis
prevents dissociation of TTR into monomers and formation of amyloid.
Objectives: To evaluate cardiac safety and tolerability of tafamidis in
patients with non-V30M TTR-FAP.
Methods: Patients (N=21) with TTR-FAP due to non-V30M TTR muta-
tions and no OLT history were studied in a phase 2 open-label trial. Cardiac
assessments included ECG, 24-hour Holter monitoring, echocardiogram,
and cardiac biomarkers (troponin I and NT-pro-BNP) at baseline and 6 and
12 months.
Results: Of the 21 patients enrolled, mean (SD) age, LVEF, troponin I,
and NT-pro-BNP at baseline were 63.1 (9.86) years, 60.3 (9.96)%,
0.023(0.04) ng/mL, and 1248.9 (1529.4) pg/mL, respectively. Nine patients
had a history of cardiac events. Six of these 9 experienced peripheral edema
or dyspnea related to heart failure while on treatment, and 3 patients were hos-
pitalized for other cardiovascular events (AV block, coronary stenosis, TIA).
Eighteen patients completed the study, with no significant changes in troponin
I, LVEF, or cardiac remodeling. NT-pro-BNP, while elevated at baseline,
remained stable with no clinically relevant changes. The pattern of Holter
monitoring abnormalities was similar at baseline and while on treatment (eg,
atrial tachycardia, 52.4% [11/21] vs 44.4% [4/9]). The percentage of patients
with normal heart rate variability (HRV) increased from 21% (4/19) at base-
line to 42% (8/19) at month 12.
Discussion: This study showed no deleterious effects of tafamidis on car-
diac function among a cohort of treated TTR-FAP patients. The number of
patients with normal HRV improved.
Conclusion: Tafamidis was safe and well tolerated in patients with non-
V30M TTR-FAP.
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Pupose: Diastolic Left ventricular (LV) dysfunction is a common finding
in sickle cell disease. Furthermore, left atrial (LA) size usually reflects left
ventricular filling pressures.
The aim of our study was to determine if LA size is an expression of left
ventricular filling pressures or reflects remodelling associated with anemia
and/or haemolysis in sickle cell disease.
Methods: We evaluated 127 patients with sickle cell disease in stable
condition (mean age 28,6±8,5 years, 83 women) and 38 age and sex-matched
healthy controls. LA size was measured with Simpson’s method in apical 4-
chamber view. LV filling pressures were assessed using ratio between pulsed
Doppler peak E velocity and peak Ea velocity obtained with tissue Doppler
imaging of the lateral annulus (E/Ea ratio). Clinical and biologic data were
collected from clinical records.
Results: Compared with the normal group, patients with sickle cell disease
had a LA volume and E/Ea ratio significatively increased (48,4±11,2 ml/m²
and 5,9±1,7 ; 30,5±7,6 ml/m² and 4,5±1, respectively, p<0.0001).
In multivariate analysis, LA enlargement in patients is only influenced by
age and haematological parameters (haemoglobin and reticulocyte levels).
No correlation was found between LA volume and E/Ea ratio (figure). 
Conclusion: Subjects with sickle cell disease have LA enlargement. However,
in this population, LA dilatation is not an index of left ventricular filling pressures.
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Background: Several arrhythmias were reported in myotonic dystrophy
(MD). The most frequent would be conduction disturbances and ventricular
arrhythmias. The purpose of the study was to evaluate the prevalence of atrial
flutter and fibrillation (AF) in MD and the consequences.
Methods: 157 patients, 80 men and 77 women, aged from 16 to 70 years,
mean age 41±14 years, at the inclusion, were consecutively recruited for a
type 1 MD. Patients were asymptomatic at the inclusion, except 4. Patients
were followed during 4.5±3.5 years. ECG, left ventricular ejection fraction
(LVEF) determination at echocardiography, Holter monitoring, signal-aver-
aged ECG were obtained and repeated.
Results: 24 patients presented sustained (> 1 hour) AF or atrial flutter
(n=8). The prevalence was 15%. Among these patients 2 presented a 1/1 atrial
flutter associated with syncope. In one of them, 16 years old, cardiac defibril-
lator was implanted for a diagnosis of ventricular tachycardia, but the real diag-
nostis was made after inappropriate shocks. Atrial flutter ablation was performed
in 4 patients but 3 of them developed AF. During follow-up, 21 patients died
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